A federal health agency that quietly underpins some of the United States’ most important patient-safety protections is facing a crisis that researchers say could reverberate through hospitals, clinics, and medical decision-making for years. In a commentary published in Annals of Internal Medicine, Aaron E. Carroll, MD, MS, and David Atkins, MD, MPH, warn that staffing reductions, disrupted funding, and organizational changes at the Agency for Healthcare Research and Quality, or AHRQ, threaten the nation’s ability to measure whether health care is becoming safer and more effective. The authors argue that the consequences may be difficult to see immediately because AHRQ’s work often operates behind the scenes. Yet its research supplies the evidence, data systems, standards, and implementation tools used to identify preventable harm and improve care across the health system.
AHRQ occupies a distinctive position in American medicine. Unlike agencies focused primarily on biomedical discovery, infectious disease control, or the regulation of drugs and devices, AHRQ is specifically charged with studying how health care is delivered and how it can be improved. Its work includes research on diagnostic errors, hospital-acquired complications, primary care, maternal health, care coordination, health disparities, and the safety of complex clinical systems. The agency also supports evidence reviews and practical programs designed to translate research findings into routine clinical practice. This type of health services research examines not only whether an intervention works under controlled conditions, but also whether clinicians can use it reliably in real-world settings, whether patients benefit, and whether improvements persist over time.
The commentary describes a series of administrative actions under the Trump administration that the authors say have weakened AHRQ’s capacity to perform that role. At least 115 previously approved research projects have been canceled, according to the authors, raising concerns about the loss of studies that address problems no other federal agency is specifically responsible for investigating. Research programs can take years to design, recruit participants for, and analyze. When projects are halted after approval, the damage is not limited to a single unanswered question. Research teams may lose specialized personnel, participating hospitals may withdraw, and data collection may stop before investigators can establish statistically reliable results. In fields such as patient safety, where adverse events may be relatively uncommon but highly consequential, incomplete datasets can make it impossible to distinguish a genuine safety signal from random variation.
The authors emphasize that diagnostic error is one area where the loss of federal research infrastructure could be particularly serious. Diagnostic safety research examines failures across the entire clinical pathway, from the patient’s first description of symptoms to history-taking, physical examination, testing, interpretation, communication, and follow-up. A missed or delayed diagnosis may result from an individual mistake, but it can also arise from poorly designed electronic health record interfaces, fragmented care, abnormal test results that are not tracked, or communication failures between clinicians. Understanding these events requires standardized definitions and large, carefully assembled datasets. Without national coordination, hospitals may measure diagnostic error in incompatible ways, leaving policymakers and clinicians unable to compare performance or determine which interventions actually reduce harm.
Maternal health provides another example of the type of problem the authors say could be neglected. Maternal complications and deaths are influenced by clinical care, access to services, socioeconomic conditions, chronic disease, and the organization of emergency response. Improving outcomes requires more than identifying a single drug or procedure. Researchers must examine how hospitals recognize warning signs, escalate care, coordinate obstetric and medical teams, and review cases after complications occur. AHRQ-supported work can help convert those observations into safety protocols and quality measures. If such projects disappear, clinicians may have fewer reliable tools for evaluating whether changes in practice are reducing severe bleeding, hypertensive emergencies, infections, and other potentially preventable complications during pregnancy and after delivery.
The disruption also threatens the evidence base used in primary care, where many important clinical decisions occur under conditions of uncertainty. Primary care clinicians often manage multiple conditions simultaneously, interpret incomplete information, and coordinate referrals across disconnected health systems. Studies supported by AHRQ can evaluate care models that use team-based practice, electronic reminders, pharmacist involvement, telehealth, or enhanced follow-up to improve outcomes. Technical success in a clinical trial does not guarantee that an intervention will work in an ordinary practice with limited staff and competing demands. Health services researchers therefore examine implementation fidelity, workflow, clinician burden, patient adherence, and cost. Losing that research may leave health systems with promising ideas but little evidence about how to deploy them safely or equitably.
Carroll and Atkins also point to the importance of the United States Preventive Services Task Force, an independent panel whose recommendations influence screening and preventive care throughout the country. The task force evaluates evidence using systematic methods that weigh benefits, harms, and the certainty of available research. Its recommendations are not simply lists of medical opinions; they depend on structured evidence reviews and judgments about whether an intervention improves health outcomes for specific populations. The authors urge Congress to press the agency to resume regular task force meetings. Interruptions could delay updates to recommendations as new studies emerge, creating uncertainty for clinicians, insurers, employers, and patients deciding when preventive services are appropriate.
The broader concern is that dismantling AHRQ could weaken the feedback loop that allows the health system to learn from its failures. In engineering terms, patient safety depends on detecting hazards, analyzing their causes, testing corrective measures, and monitoring whether those measures work. A hospital may introduce a checklist or computerized alert, but without rigorous evaluation it may not know whether the intervention prevents errors, merely shifts them elsewhere, or creates new burdens that cause clinicians to ignore important warnings. National agencies can provide common definitions, independent analysis, and long-term continuity that individual hospitals may lack. They can also study low-frequency events whose investigation would be too expensive or statistically difficult for a single institution.
The authors’ warning arrives as public trust in health institutions is already under pressure and as clinicians face increasing demands to demonstrate that care is safe, effective, and worth its cost. If AHRQ’s research pipeline remains disrupted, the effects may appear gradually: fewer validated safety measures, slower updates to clinical guidance, less information about diagnostic failures, and diminished capacity to evaluate reforms before they are widely adopted. Carroll and Atkins call on Congress to mitigate the damage by restoring the agency’s ability to conduct and coordinate research and by supporting the regular operation of the preventive services task force. Their central message is that health care quality is not maintained automatically. It depends on an ongoing scientific infrastructure capable of measuring what happens to patients, explaining why it happens, and testing whether the system can do better.
Subject of Research: People
Article Title: AHRQ on the Brink: The Trump Administration Assault on the Agency for Healthcare Research and Quality
News Publication Date: 18 August 2026
Web References: https://doi.org/10.7326/ANNALS-26-03490
References: Carroll AE, Atkins D. “AHRQ on the Brink: The Trump Administration Assault on the Agency for Healthcare Research and Quality.” Annals of Internal Medicine. DOI: 10.7326/ANNALS-26-03490.
Keywords: Health care quality, patient safety, Agency for Healthcare Research and Quality, AHRQ, diagnostic errors, maternal health, primary care, health services research, preventive care, United States Preventive Services Task Force, public health, health care delivery
Tags: AHRQ funding and staffing reductionseffects of federal healthcare policy changeshealthcare disparities and vulnerable populationshealthcare quality improvementhealthcare quality measurement challengeshospital and clinic safety standardsimpact of organizational changes on healthcare qualityimpact on healthcare research and data systemsimportance of healthcare research agenciespatient safety protectionsprevention of medical errors and complicationsrole of AHRQ in medical decision-making
